Phase III Trial: Iodine 124 Evuzamitide Meets Primary Endpoints in Detecting Cardiac Amyloidosis

Bayer’s investigational PET tracer, Iodine 124 evuzamitide, met primary endpoints in a Phase III study involving patients suspected of having cardiac amyloidosis. The study assessed the efficacy of the tracer in identifying and characterizing cardiac amyloidosis, a condition where abnormal protein deposits accumulate in the heart.

Specifically, the Phase III trial evaluated Iodine 124 evuzamitide’s ability to accurately detect cardiac amyloidosis through PET imaging. Researchers focused on the tracer’s performance in visualizing amyloid deposits in the heart, which is crucial for diagnosing and managing the disease. The successful achievement of the primary endpoints suggests that Iodine 124 evuzamitide holds promise as a diagnostic tool for cardiac amyloidosis.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI